A Case about Use of Mycophenolate Mofetil in Acute Renal Failure Associated with Lupus Nephritis.
- Author:
Mi Jeong PARK
1
;
Hyun Ju KIM
;
Hwa Mok LEE
;
Joon Seok OH
;
Hyun Cheol HWANG
;
Dong Han IM
;
Hoe Joo OH
;
Yong Ki PARK
;
Yong Hun SHIN
;
Joong Kyung KIM
Author Information
1. Department of Internal Medicine, Bong Saeng Hospital, Busan, Korea. syhpmj@hanmail.net
- Publication Type:Case Report
- Keywords:
Systemic lupus erythematosus (SLE);
Lupus nephritis;
Mycophenolate mofetil
- MeSH:
Acute Kidney Injury*;
Adrenal Cortex Hormones;
Autoimmune Diseases;
Creatinine;
Cytotoxins;
Diuretics;
Edema;
Female;
Follow-Up Studies;
Humans;
Lupus Nephritis*;
Oliguria;
Organ Transplantation;
Proteinuria;
Renal Dialysis;
Transplants;
Young Adult
- From:Korean Journal of Nephrology
2006;25(4):635-639
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Mycophenolate mofetil (MMF) is a immunosuppressive agent increasingly used in organ transplantation and autoimmune disease. We report a case about use of MMF in SLE patient with rapidly worsening renal function. A 24-year old female was admitted due to 1-week history of generalized edema. Despite use of diuretics and conventional supported care, generalized edema was more aggravated and serum creatinine was elevated up to 5.2 mg/dL. Ten days after the initial admission, we started hemodialysis. After hemodialysis, improvement of generalized edema was achieved. Eighteen days after initial hemodialysis, we started corticosteroids and MMF because she shows persistent heavy proteinuria and oliguria. After use of corticosteroids and MMF, clinical improvement of renal complication was achieved in this patient. About 6 weeks later, we could discontinue hemodialysis. On two year follow up duration, she shows good renal function and no evidence of lupus flare-up signs. We suggest MMF is one of therapeutic options for patients with severe lupus nephritis, especially those refractory or intolerant to conventional cytotoxic agents.
